HPV vaccine after LEEP to help prevent cervical lesion relapse
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether getting the HPV vaccine after a LEEP procedure helps prevent the cervical problem from coming back. You may be eligible if you had a high-grade cervical pre-cancer or very early cancer, and have not had an HPV vaccine before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your health is good enough for daily activities (ECOG 0–1, not ECOG 2 or more)
- You have a confirmed high-grade cervical problem or very early cancer (at least CIN2, up to stage Ia1)
- You have never had an HPV vaccine before, and you don’t have a fever at vaccination
- You can understand and write Italian, and you sign consent forms
- You are not pregnant (negative pregnancy test at vaccination)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an HPV vaccine after a cone biopsy (a surgery to remove abnormal cells from the cervix) helps prevent the HPV-related disease from coming back. It may be an option for patients who have had treatment for cervical dysplasia and have not been vaccinated against HPV before.
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study tests a new HPV vaccine (V503, known as Gardasil 9) in Chinese women who either previously received the bivalent HPV vaccine (Cervarix) more than a year ago or never had any HPV vaccine. The goal is to see if this vaccine can effectively prevent HPV-related diseases.
Hear when a new Cervical Intraepithelial Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.